Device Trial Radar · NCT07804199
taVNS in Veterans With Knee OA (AVAHCS)
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 29, 2026
Primary completion
Jan 1, 2028
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to identify an optimal transcutaneous auricular vagus nerve stimulation (taVNS) dosing regimen for pain relief and anti-inflammatory effects in Veterans with knee osteoarthritis (OA), compared to corticosteroid injection (CSI), and lay the groundwork for future combinatorial therapies with cell-based approaches. The population for this study is Veterans with osteoarthritis (OA). This single-center, randomized pilot study will enroll participants with knee OA, who will be allocated to CSI (n=10), high-dose taVNS (n=15; 1-2 hours/day, 7 days/week), or low-dose taVNS (n=15; 30-60 min/day, 3 days/week) for 12 weeks. Synovial fluid and blood samples will be collected at baseline, 4, and 12 weeks for biomarker analysis (pro-inflammatory cytokines: TNF-, IL-6, IL-1 ; anti-inflammatory mediators: IL-10, TGF-). The approximate study duration for each individual participant is 12 weeks of treatment with assessment visits at baseline, one month, and three months. Participants will be recruited at the Atlanta VA. The anticipated total enrollment is 40 participants. No specimens or data will be banked for future research use. Informed consent will be obtained from participants in person via signatures on written informed consent forms.
Conditions
- Knee Osteoarthritis
Interventions
Methylprednisolone acetateDrug
FDA-approved injection treatment applied to the knee for purposes of KOA pain management.
taVNSDevice
Transcutaneous auricular vagus nerve stimulation (taVNS) is a self-administered, home-based, non-invasive therapy with minimal risk of side effects. Mechanistically, taVNS targets auricular vagal afferents and requires afferent signaling to the nucleus tractus solitarius (NTS) to activate downstream efferent pathways in the central nervous system, including higher brain regions involved in pain processing (Fig 1), exerting anti-nociceptive effects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvements in Clinical Pain (DVPRS)Time frame: Through study completion, average of 9 months
- Concentration of Pro-inflammatory Cytokines (Blood)Time frame: Through study completion, average of 9 months
- Concentration of Pro-inflammatory Cytokines (Synovial Fluid)Time frame: Through study completion, average of 9 months
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Atlanta VA Medical and Rehab Center, Decatur, GA
Decatur, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.